Medherant | Interview with CEO John Burt

25th January, 2021

Medherant is a spin-out from the University of Warwick, and is a clinical-stage company developing innovative treatments for pain and CNS diseases using its novel transdermal drug delivery technology.

In this insightful interview, CEO John Burt explains why its transdermal drug delivery system offers an alternative route of administration for drugs that are not ideally suited to oral administration, describes its lead product for smoking cessation, how Mercia’s support has helped Medherant in seeking new challenges, and how the last 18 months has seen the business collaborate with a number of pharma companies leading to the commercialisation of multiple products using its technology.

Are you looking to grow your business?

Loading...